Literature DB >> 8384110

Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats.

S Prendiville1, K Gale.   

Abstract

Fluoxetine was evaluated for anticonvulsant effects in a rat model of focally evoked complex partial seizures (CPS) secondarily generalized. Fluoxetine was administered intraperitoneally (i.p.) 1 h before seizures were induced by focal intracerebral application of the GABAA receptor antagonist, bicuculline methiodide (118 pmol) unilaterally into a discrete epileptogenic site in the deep prepiriform cortex ("area tempestas," AT) of rats. Significant dose-dependent protection from clonic motor seizures was obtained after 5-, 10-, and 20-mg/kg doses of fluoxetine, with 50% protection occurring after the 5-mg/kg dose. Suppression of electrographic seizure activity was concomitant with suppression of motor seizures. These observations support and extend previous findings of other investigators who showed that fluoxetine exerts anticonvulsant actions against maximal electroshock (MES) convulsions and audiogenic convulsions in genetically seizure-prone rodents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384110     DOI: 10.1111/j.1528-1157.1993.tb02425.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  15 in total

1.  Successful treatment of epilepsy with serotonin reuptake inhibitors: proposed mechanism.

Authors:  C Albano; A Cupello; P Mainardi; S Scarrone; E Favale
Journal:  Neurochem Res       Date:  2006-05-13       Impact factor: 3.996

Review 2.  Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy.

Authors:  Amy R Brooks-Kayal; Kevin G Bath; Anne T Berg; Aristea S Galanopoulou; Gregory L Holmes; Frances E Jensen; Andres M Kanner; Terence J O'Brien; Vicky H Whittemore; Melodie R Winawer; Manisha Patel; Helen E Scharfman
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

Review 3.  Can Neurochemical Changes of Mood Disorders Explain the Increase Risk of Epilepsy or its Worse Seizure Control?

Authors:  Andres M Kanner
Journal:  Neurochem Res       Date:  2017-07-01       Impact factor: 3.996

4.  Time course of changes in the concentrations of monoamines in the brain structures of pentylenetetrazole-kindled rats.

Authors:  Janusz Szyndler; Piotr Maciejak; Danuta Turzyńska; Alicja Sobolewska; Andrzej Bidziński; Adam Płaźnik
Journal:  J Neural Transm (Vienna)       Date:  2010-05-07       Impact factor: 3.575

5.  Serotonin abnormalities in Dravet syndrome mice before and after the age of seizure onset.

Authors:  Paul G Hatini; Kathryn G Commons
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

6.  Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the WAG/Rij rat model of absence epilepsy.

Authors:  Rita Citraro; Antonio Leo; Pasquale De Fazio; Giovambattista De Sarro; Emilio Russo
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

Review 7.  Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?

Authors:  L Cardamone; M R Salzberg; T J O'Brien; N C Jones
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 8.  Mood disorders in patients with epilepsy: epidemiology and management.

Authors:  Cynthia L Harden; Martin A Goldstein
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

9.  Epileptic seizures but not pseudoseizures are associated with decreased density of the serotonin transporter in blood platelet membranes.

Authors:  Aroldo Cupello; Daniela Audenino; Simona Scarrone; Michele Fornaro; Elena Gatta; Pantaleo Fornaro; Claudio Albano
Journal:  Neurochem Res       Date:  2008-04-22       Impact factor: 3.996

Review 10.  Therapeutic potential of fluoxetine in neurological disorders.

Authors:  Jop P Mostert; Marcus W Koch; Marco Heerings; Dorothea J Heersema; Jacques De Keyser
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.